X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
veliparib (55) 55
index medicus (53) 53
oncology (50) 50
humans (47) 47
poly polymerase (30) 30
female (28) 28
cancer (26) 26
parp inhibitor (26) 26
abt-888 (25) 25
aged (21) 21
chemotherapy (21) 21
middle aged (20) 20
combination (19) 19
phase-i (19) 19
benzimidazoles - administration & dosage (18) 18
pharmacology & pharmacy (17) 17
tumors (17) 17
adult (16) 16
male (16) 16
analysis (15) 15
article (15) 15
benzimidazoles - pharmacokinetics (14) 14
dna damage (14) 14
care and treatment (13) 13
deoxyribonucleic acid--dna (13) 13
poly polymerase inhibitors - therapeutic use (13) 13
adp-ribose polymerase (12) 12
benzimidazoles - adverse effects (12) 12
dna repair (12) 12
homologous recombination (12) 12
veliparib abt-888 (12) 12
animals (11) 11
brca2 protein - genetics (11) 11
mutation (11) 11
olaparib (11) 11
ovarian-cancer (11) 11
parp (11) 11
parp inhibitors (11) 11
pharmacokinetics (11) 11
poly polymerase inhibitors (11) 11
benzimidazoles - pharmacology (10) 10
breast cancer (10) 10
cell line, tumor (10) 10
ovarian cancer (10) 10
pharmacology (10) 10
solid tumors (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
benzimidazoles - therapeutic use (9) 9
brca1 protein - genetics (9) 9
poly polymerase inhibitor (9) 9
poly polymerase inhibitors - pharmacology (9) 9
radiation (9) 9
temozolomide (9) 9
aged, 80 and over (8) 8
breast-cancer (8) 8
dacarbazine - analogs & derivatives (8) 8
dose-response relationship, drug (8) 8
inhibitor (8) 8
medicine & public health (8) 8
monosaccharides (8) 8
patients (8) 8
poly polymerase inhibitors - administration & dosage (8) 8
sugars (8) 8
survival (8) 8
therapy (8) 8
toxicity (8) 8
antimitotic agents (7) 7
antineoplastic agents (7) 7
brca (7) 7
brca1 (7) 7
breast neoplasms - drug therapy (7) 7
breast neoplasms - pathology (7) 7
clinical trials (7) 7
dna-repair (7) 7
drug synergism (7) 7
inhibitors (7) 7
mice (7) 7
pharmacology/toxicology (7) 7
poly polymerase inhibitors - adverse effects (7) 7
poly polymerases - metabolism (7) 7
refractory solid tumors (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
breast neoplasms - genetics (6) 6
cancer research (6) 6
cells (6) 6
cisplatin (6) 6
drug resistance, neoplasm (6) 6
hematology, oncology and palliative medicine (6) 6
in-vitro (6) 6
leukemia (6) 6
neoplasms - drug therapy (6) 6
ovarian neoplasms - drug therapy (6) 6
parp inhibition (6) 6
poly polymerase inhibitors - pharmacokinetics (6) 6
repair (6) 6
research (6) 6
treatment outcome (6) 6
trial (6) 6
adp (5) 5
anticancer properties (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2017, Volume 57, Issue 8, pp. 977 - 987
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2016, Volume 22, Issue 12, pp. 2855 - 2864
Journal Article
Journal Article
Neuro-Oncology, ISSN 1522-8517, 2014, Volume 16, Issue 12, pp. 1661 - 1668
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2014, Volume 32, Issue 5, pp. 904 - 912
Journal Article
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2017, Volume 144, Issue 3, pp. 486 - 490
Journal Article
CANCER CHEMOTHERAPY AND PHARMACOLOGY, ISSN 0344-5704, 11/2016, Volume 78, Issue 5, pp. 1003 - 1011
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 11/2015, Volume 76, Issue 5, pp. 1063 - 1072
Veliparib is a potent, orally bioavailable PARP inhibitor that enhances efficacy of DNA-damaging chemotherapeutic agents. The study objectives were to... 
Medicine & Public Health | Veliparib (ABT-888) | NSCLC | Paclitaxel | Carboplatin | Oncology | Cancer Research | PARP | Pharmacology/Toxicology | SURVIVAL | TRIAL | THERAPY | ONCOLOGY | POLYMERASE INHIBITOR | PHARMACOLOGY & PHARMACY | DNA-REPAIR | Lung Neoplasms - drug therapy | Area Under Curve | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Poly(ADP-ribose) Polymerase Inhibitors - blood | Carboplatin - adverse effects | Dose-Response Relationship, Drug | Benzimidazoles - administration & dosage | Adult | Female | Paclitaxel - blood | Benzimidazoles - adverse effects | Paclitaxel - administration & dosage | Benzimidazoles - blood | Carcinoma, Non-Small-Cell Lung - pathology | Drug Eruptions - etiology | Hematologic Diseases - chemically induced | Japan | Poly(ADP-ribose) Polymerase Inhibitors - pharmacokinetics | Benzimidazoles - pharmacokinetics | Carboplatin - administration & dosage | Carboplatin - blood | Paclitaxel - adverse effects | Combined Modality Therapy | Lung Neoplasms - therapy | Poly(ADP-ribose) Polymerase Inhibitors - adverse effects | Tumor Burden | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Drug Synergism | Radiography | Carcinoma, Non-Small-Cell Lung - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lung Neoplasms - diagnostic imaging | Aged | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Carcinoma, Non-Small-Cell Lung - drug therapy | Chemotherapy | Anemia | Analysis | Amino acids | Lung cancer, Small cell | Lung cancer, Non-small cell | Cancer | Index Medicus | Original
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 2010, Volume 52, Issue 1, pp. 122 - 128
Journal Article